iRegene Therapeutics
Cell Therapy Product Developer
2025Year10Month6Day, iRegeneCo., Ltd. (iRegene Therapeutics) , a global leading chemical inductionSpot General TypeCell Therapy Innovation Enterprise,In2025Globally Focused in ...International Parkinson's Disease and Movement Disorders Conference (MDS Congress) Above, invited to participate in the world's firstiPSCSource Chemically-Induced Universal Dopaminergic Neural Precursor Cells (NouvNeu001) A groundbreaking study on the treatment of moderate to severe Parkinson's disease was presented orally.
Its unique chemical induction platform, and the clinical transformation of its unique advantagesIThe significant treatment data from the period has garnered substantial attention from numerous clinical experts, investment institutions, international large pharmaceutical companies, and research institutes present at the conference.
It is worth mentioning that this time iRegeneNouvNeu001AsInternational Parkinson's Disease and Movement Disorders ConferenceThe opening report of the clinical trial session not only representsInternational Parkinson's Disease and Movement DisordersThe association's recognition of iRegene's work further highlights the acknowledgment from international professional institutions towards iRegene.NouvNeu001Attention and encouragement for pioneering work in the field of Parkinson's treatment.
Core Technology Breakthrough: Chemical Induction Platform Builds Competitive Barrier
iRegeneCEODr. Jun Wei, representing the iRegene team and the clinical trial team, presented the unique advantages of iRegene's chemical induction platform at the conference.NouvNeu001ClinicalIThe significant breakthrough data in this phase originated from iRegene's proprietary chemical induction platform and optimized clinical strategies. iRegene utilized its proprietary chemical induction system to...iPSCInduction of groundbreaking high-purity, functionally enhanced dopaminergic specific subtype precursor cells,And for the first time internationally adopted”Patient Benefit First”Single-needle stereotactic drug delivery method,Significantly reduce surgical risks and related adverse events.
Chemical induction platform not only in preclinical researchShowcaseShowing significant advantages, its therapeutic benefits have also been demonstrated in clinical settings.IThis period has also been further validated: iRegene's chemical induction platform has optimized the immunogenicity of universal cell products for safety, therefore,The patient did not experience immune rejection after discontinuing the use of immunosuppressants in the sixth month post-operation.RelevantAdverse Event.
Moreover, mature neurons at the large cohort level of subjectsPETImagingResultsAlso furtherConfirm了NouvNeu001After TransplantationInILarge Cohort of SubjectsBrainDepartment ofLong-term Survival and StabilityExcellent ability in differentiation and integration。
Clinical Data Shines: Multi-dimensional Improvement in Symptoms of Parkinson's Patients
iRegene's chemical induction platform has achieved targeted modification and enhancement of the therapeutic functions of dopamine neurons, therefore,NouvNeu001SubjectTheMDS-UPDRS TheIIIPartial Score (Motor Function Score)After transplantation, there wasSignificant Improvement:AdministrationAfter12Months,UPDRS-IIIScore inOFFStatusAverage Improvement30.6Minute(Improvement amplitude averaged over baseline is52.82%），ONStatusAverage Improvement12.9Minute(Compared to the baseline, the average improvement was54.67%), the improvement in multiple indicators was statistically significant, surpassing international competitors and other treatment options.And in15Presented a sustained improvement effect months later.
In addition, standardizationGood ON TimeMultiple non-motor symptoms also showed significant improvement after treatment.
The above-mentioned clinical with statistical significanceIThe data further confirms the unique technical advantages of iRegene's pioneering chemical induction platform.
Breaking into the International Top Tier: Accelerating the Global Clinical Layout
Notably, as a special session for pharmaceutical companies' clinical trial reports, the clinical progress was presented alongside iRegene, and also included presentations from companies such asBlueRock，Roche，BiogenInnovative products from well-known international large pharmaceutical companies in the field of Parkinson's disease new drug development represent the strongest lineup in this area.
iRegene Chief Medical OfficerDr. Cai Meng, an academic official, also attended the conference during the same period and discussed with many international experts in the field.Multiple Topics in Clinical Trials for New Parkinson's Disease Drug Development: A Review and Outlook on the Latest Advances and Future R&D Strategies of Renowned Pharmaceutical Companies in China and Abroad in Disease-Modifying Therapies for Parkinson’s Disease.
Dr. Cai Meng stated:“This time, we exchanged ideas with many international peers.Cell Therapy for Parkinson's DiseaseIn Clinical TrialsMultipleCore topics, gained a lot, and received recognition from international peers, which is iRegene's effort to advance the international industry.Important MilestonesEvent, International Peers and ClinicalPIVery much looking forward to it.NouvNeu001Clinical manifestations overseas. WeWill continue to accelerateCompletedNouvNeu001TheII`Clinical Trial Period`And International MulticenterIPhase Clinical Trial", firmly committed to bringing breakthrough therapies to patients with Parkinson's disease."
From technological innovation to clinical validation, from China-originated to globally recognized, iRegene has relied onNouvNeu001A breakthrough progress has opened up a new path in the field of Parkinson's disease cell therapy.
As clinical trials continue to progress, we have reason to expect that this world-first cell therapy product will soon benefit more patients, paving the way for Parkinson's disease treatment.“China Solution”Win more international applause.
